Heart Failure and Aortic Stenosis Transcriptome
Launched by IRCCS POLICLINICO S. DONATO · Aug 28, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying heart failure and aortic stenosis, which are serious heart conditions. The researchers want to understand the role of certain types of RNA (which are important for gene expression) in these conditions. They will collect blood and tissue samples from patients to compare their RNA profiles to those of people without heart disease. This research could help identify new ways to diagnose and treat these heart issues.
To participate, you should be between 40 and 75 years old and have specific types of heart failure or aortic stenosis that meet the study's criteria. For example, if you have heart failure, you should not be at the end stage of the disease and should have certain measurements related to heart function. If you decide to join, you will provide samples and help researchers learn more about these conditions, which could benefit patients in the future. Please note that certain health conditions or treatments may exclude you from the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Non end-stage heart failure
- • left ventricle restoration surgery (SVR)
- • End Systolic Volume Index (ESVI) \>35 ml/m2
- • Ejection Fraction (EF)\<40%
- • previous transmural anterior myocardial infarction (MI)
- • age: 40-75
- • 2. End-stage heart failure
- • left ventricle assisted device (LVAD) surgery
- • age: 40-75
- • Ejection Fraction (EF) \<25%
- • End Systolic Volume Index (ESVI)≥60 ml/m2
- • 3. Aortic Stenosis
- • aortic valve replacement
- • intracardial pressure difference \>40 mmHg
- • septal diameter ≥1.3 cm
- Exclusion Criteria:
- • 1. Non end-stage heart failure
- • End Systolic Volume Index (ESVI)\<35 ml/m2
- • Ejection Fraction (EF)\>40%
- • Time from MI unknown
- • Pregnancy
- • Other genetic diseases
- • Neoplasms
- • Collagenopathies
- • Chemo/radiotherapy
- • Prolonged use of corticosteroids
- • Infections
- • Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive
- • 2. End-stage heart failure
- • EF\>25%
- • Time from MI unknown
- • Pregnancy
- • Other genetic diseases
- • Neoplasms
- • Collagenopathies
- • Chemo/radiotherapy
- • Prolonged use of corticosteroids
- • Infections
- • Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive
- • 3. Aortic Stenosis
- • coronaropathies
- • Pregnancy
- • Other genetic diseases
- • Neoplasms
- • Collagenopathies
- • Chemo/radiotherapy
- • Prolonged use of corticosteroids
- • Infections
- • Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive
About Irccs Policlinico S. Donato
IRCCS Policlinico S. Donato is a leading Italian research hospital and clinical trial sponsor dedicated to advancing medical science through innovative research and patient care. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it is recognized for its commitment to high-quality clinical research and the integration of scientific investigation with clinical practice. The institution specializes in various medical fields, including cardiology, oncology, and neurology, and collaborates with universities and research organizations to facilitate cutting-edge studies. With a focus on improving patient outcomes and contributing to public health, IRCCS Policlinico S. Donato plays a pivotal role in the development of new therapies and treatment protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
San Donato Milanese, Milan, Italy
Patients applied
Trial Officials
Fabio Martelli, Dr
Principal Investigator
IRCCS Policlinico S. Donato
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials